← Back to Search

Nonsteroidal Anti-inflammatory Drug

Ketorolac vs Triamcinolone Injections for Tendinopathy or Arthritis

Phase 4
Recruiting
Led By Amanda L Dempsey
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18 or older
Symptomatic tendinopathy or arthropathy of the hand or wrist who have not undergone prior surgical treatment for their condition
Must not have
Patients under the age of 18
Patients who have undergone prior surgical treatment for their hand condition
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 6 weeks, 24 weeks
Awards & highlights
Pivotal Trial
No Placebo-Only Group
Drug Has Already Been Approved

Summary

This trial is testing two types of injections, ketorolac and triamcinolone, to help patients with painful conditions in their shoulder, elbow, wrist, and hand. These injections aim to reduce inflammation and pain, improving movement and function. Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) known for its potent nonopioid pain-relieving activity, effective in treating moderate to severe pain, especially after surgery.

Who is the study for?
Adults with painful conditions of the hand or wrist, like trigger finger, De Quervain's tenosynovitis, or osteoarthritis in certain joints. They shouldn't have had surgery for these issues before. People under 18, those who've had similar injections recently, with allergies to the drugs used, or an active infection at the injection site can't join.
What is being tested?
The trial is testing if Ketorolac or Triamcinolone injections help reduce pain and improve function in patients with tendinopathy or arthropathy of the shoulder, elbow, wrist, and hand. Participants won't know which treatment they get and will be followed up after 6 weeks.
What are the potential side effects?
Possible side effects from Ketorolac might include gastrointestinal problems like ulcers and bleeding; kidney damage; allergic reactions; increased blood pressure. Triamcinolone may cause joint pain increase initially; skin discoloration; weakening of bones.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have hand or wrist joint pain without previous surgery for it.
Select...
I have painful tendon or joint issues in my hand or wrist and haven't had surgery for it.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am under 18 years old.
Select...
I have had surgery for my hand condition before.
Select...
I am allergic or cannot take triamcinolone or ketorolac injections.
Select...
I do not have an infection at the treatment site.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 6 weeks, 24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 6 weeks, 24 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Changes in Visual Analog Scale (VAS) pain score
Secondary study objectives
Changes in Grip Strength
Changes in Hand subjectivity value
Changes in Key Pinch
+2 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.

Trial Design

2Treatment groups
Active Control
Group I: Triamcinolone injection to the shoulder, elbow, wrist, or handActive Control1 Intervention
Participants will receive the triamcinolone injection solutions in a standard fashion. Injections will be performed using the treating physician's standard technique.
Group II: Ketorolac injection to the shoulder, elbow, wrist, or handActive Control1 Intervention
Participants will receive the Ketoralac injection solutions in a standard fashion. Injections will be performed using the treating physician's standard technique.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for tendinopathy include NSAIDs like Ketorolac and corticosteroids like Triamcinolone. NSAIDs inhibit the enzyme cyclooxygenase (COX), reducing the production of prostaglandins that cause inflammation and pain. Corticosteroids suppress the immune response and decrease inflammation by inhibiting multiple inflammatory pathways. These mechanisms are crucial for tendinopathy patients as they help manage pain and inflammation, facilitating better participation in physical therapy and improving overall function.
[Should athletic injuries be treated with non-steroidal anti-rheumatic agents (NSAID)? Tenoxicam, piroxicam and placebo in the treatment of acute stress-induced injuries].Effects of nonsteroidal anti-inflammatory drugs on flexor tendon adhesion.Inhibition of tendon cell proliferation and matrix glycosaminoglycan synthesis by non-steroidal anti-inflammatory drugs in vitro.

Find a Location

Who is running the clinical trial?

American Association for Hand Surgery: AAHSUNKNOWN
Emory UniversityLead Sponsor
1,703 Previous Clinical Trials
2,606,864 Total Patients Enrolled
2 Trials studying Tendinopathy
184 Patients Enrolled for Tendinopathy
American Association for Hand SurgeryUNKNOWN

Media Library

Ketorolac (Nonsteroidal Anti-inflammatory Drug) Clinical Trial Eligibility Overview. Trial Name: NCT05292339 — Phase 4
Tendinopathy Research Study Groups: Triamcinolone injection to the shoulder, elbow, wrist, or hand, Ketorolac injection to the shoulder, elbow, wrist, or hand
Tendinopathy Clinical Trial 2023: Ketorolac Highlights & Side Effects. Trial Name: NCT05292339 — Phase 4
Ketorolac (Nonsteroidal Anti-inflammatory Drug) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05292339 — Phase 4
~33 spots leftby Jul 2025